Drug Safety Assessment of Medication-Related Changes in Physical Function During Long-Term Therapy

Abstract

Medication-related changes in physical function represent a critical consideration in the long-term management of chronic diseases. This review synthesizes current evidence on the epidemiology, pathophysiology, risk factors, clinical features, diagnosis, and management of drug-induced physical function impairment, with emphasis on safety assessment and monitoring. Recent advances and guideline recommendations are discussed to aid clinicians in optimizing therapeutic strategies and mitigating adverse outcomes associated with long-term pharmacotherapy.

Introduction

Long-term pharmacotherapy is a cornerstone in the management of chronic diseases such as cardiovascular disorders, diabetes, psychiatric illnesses, and autoimmune conditions. However, sustained medication exposure may lead to adverse changes in physical function, impacting mobility, muscle strength, balance, and overall quality of life. Drug-induced physical impairment poses significant challenges for patient safety and independence, especially in older adults and those with multimorbidity. Understanding the mechanisms, clinical relevance, and strategies for drug safety assessment is essential for healthcare professionals managing these populations.

Epidemiology / Disease Burden

The prevalence of medication-related physical function declines varies widely, with estimates suggesting up to 20-30% of older adults on polypharmacy regimens experiencing functional impairment attributable to their medications. Epidemiological studies highlight that the burden is higher in populations with multiple comorbidities, polypharmacy, and in settings with limited medication review processes. Adverse drug reactions (ADRs) are among the leading causes of preventable morbidity, hospitalization, and institutionalization in elderly cohorts. Specific drug classes, such as sedatives, anticholinergics, corticosteroids, and antihypertensives, are frequently implicated.

Pathophysiology

Medication-induced changes in physical function arise through diverse mechanisms. Central nervous system (CNS) depressants, such as benzodiazepines and antipsychotics, may impair coordination and reaction time, increasing fall risk. Anticholinergic drugs interfere with neuromuscular transmission, contributing to muscle weakness and cognitive impairment. Corticosteroids can induce myopathy, osteoporosis, and metabolic derangements, all of which compromise musculoskeletal integrity. Statins may cause myalgia and, rarely, rhabdomyolysis, affecting mobility. Furthermore, drug-drug interactions can exacerbate these effects by altering pharmacokinetics or augmenting toxicity. The pathophysiology is often multifactorial, influenced by underlying health status, age-related physiological changes, and genetic predisposition.

Risk Factors

Several risk factors predispose patients to medication-related declines in physical function. Advanced age, frailty, pre-existing mobility limitations, cognitive impairment, renal or hepatic dysfunction, and polypharmacy significantly elevate risk. Pharmacogenomic variations affecting drug metabolism may also play a role. Concomitant use of multiple CNS-active agents or drugs with overlapping toxicity profiles further amplifies the likelihood of functional impairment. Inadequate medication reconciliation and lack of regular review contribute to cumulative risk over time.

Clinical Features

Clinical manifestations range from subtle declines in gait speed and grip strength to overt falls, fractures, and loss of independence. Patients may report muscle weakness, fatigue, dizziness, orthostatic hypotension, or cognitive slowing. Functional assessment tools, such as the Timed Up and Go (TUG) test, Short Physical Performance Battery (SPPB), and handgrip dynamometry, are useful in detecting early changes. Adverse effects may be mistaken for progression of underlying disease rather than recognized as drug-related, highlighting the importance of vigilance and thorough history-taking.

Diagnosis

Diagnosis involves a comprehensive medication review, clinical assessment, and functional testing. Identifying temporal associations between medication initiation or dose escalation and onset of physical decline is crucial. Laboratory investigations may reveal drug-induced electrolyte disturbances, myopathies, or metabolic abnormalities. Diagnostic algorithms integrating clinical, pharmacological, and laboratory data aid in differentiating drug-induced impairment from other causes. Clinical pharmacists play a pivotal role in evaluating potential drug-drug and drug-disease interactions contributing to functional decline.

Treatment & Management

Management focuses on mitigating risk and optimizing functional outcomes. Regular medication reconciliation, deprescribing unnecessary or high-risk agents, and selecting drugs with favorable safety profiles are key strategies. Dose adjustments, switching to alternative agents, or implementing non-pharmacological interventions may be warranted. Multidisciplinary approaches involving physicians, pharmacists, physiotherapists, and occupational therapists enhance patient monitoring and rehabilitation efforts. Patient education on potential side effects and self-monitoring is vital for early detection and intervention.

Recent Advances / Emerging Therapies

Recent advances include the development of risk prediction tools utilizing electronic health records and machine learning algorithms to identify patients at greatest risk. Pharmacogenomic testing is increasingly available, enabling personalized therapy and minimizing adverse outcomes. Novel drug formulations and delivery systems aim to reduce systemic exposure and toxicity. Ongoing research into biomarkers of drug-induced myopathy and frailty may further refine early detection and prevention strategies.

Guideline Recommendations

Contemporary clinical guidelines, including those from the American Geriatrics Society and European Society of Cardiology, emphasize routine functional assessment and medication review in all patients receiving long-term pharmacotherapy, particularly older adults. Recommendations include the use of validated screening tools for frailty and functional decline, regular monitoring for adverse drug effects, and proactive deprescribing initiatives. Interdisciplinary collaboration is advocated to ensure comprehensive care and minimize risk.

Conclusion

Medication-related changes in physical function constitute a significant yet potentially preventable contributor to morbidity in patients undergoing long-term therapy. Proactive drug safety assessment, individualized treatment planning, and ongoing monitoring are essential for optimizing patient outcomes. Continued research and implementation of guideline-directed strategies will further enhance medication safety and preserve physical function in vulnerable populations.